Therapy side-effects and predictive factors for preterm delivery in patients undergoing tocolysis with atosiban or ritodrine for threatened preterm labour
- PMID: 24959721
- DOI: 10.3109/01443615.2014.930094
Therapy side-effects and predictive factors for preterm delivery in patients undergoing tocolysis with atosiban or ritodrine for threatened preterm labour
Abstract
The objective of this study was to compare the safety and efficacy of atosiban and ritodrine in the treatment of threatened preterm labour (TPL) and to analyse the predictive factors of preterm delivery. We retrospectively sampled data on 380 women hospitalised for TPL (24-35 weeks' gestation), in our clinic between 2004 and 2007. All were subjected to tocolysis with ritodrine and/or atosiban. Data were analysed using R (version 2.12.1), considering p < 0.05 as significant. We had 69 women treated with atosiban, 242 treated with ritodrine and 69 treated with ritodrine changed for atosiban, if adverse effects occurred. In the multivariate logistic regression, the use of atosiban vs ritodrine does not play any role in delaying delivery after 48 h or 7 days, whereas the cervical change at the digital examination, high contractions pre/post-therapy ratio, pPROM, cervical length and fibronectin result as predictive factors for both delivery before 48 h or 7 days. Maternal adverse drug effects were significantly more frequent in patients treated with ritodrine, and one single case of pulmonary oedema was observed. We found fewer side-effects in the atosiban than in the ritodrine group and no difference in efficacy. Moreover, the most predictive factors for preterm delivery were fibronectin test, pPROM, digital vaginal examination and uterine contraction persistence. We believe that predictive capacity of these tests could give the opportunity for targeting therapy and limiting drug side-effects and cost.
Keywords: Atosiban; preterm delivery; ritodrine; threatened preterm labour.
Similar articles
-
Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women.BJOG. 2006 Nov;113(11):1228-34. doi: 10.1111/j.1471-0528.2006.01053.x. Epub 2006 Sep 15. BJOG. 2006. PMID: 16978233 Clinical Trial.
-
Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group.BJOG. 2001 Feb;108(2):133-42. BJOG. 2001. PMID: 11236112 Clinical Trial.
-
Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study.Am J Obstet Gynecol. 2000 May;182(5):1191-9. doi: 10.1067/mob.2000.104950. Am J Obstet Gynecol. 2000. PMID: 10819857 Clinical Trial.
-
Atosiban versus betamimetics in the treatment of preterm labour in Italy: clinical and economic importance of side-effects.Eur J Obstet Gynecol Reprod Biol. 2011 Aug;157(2):128-35. doi: 10.1016/j.ejogrb.2011.04.009. Epub 2011 May 28. Eur J Obstet Gynecol Reprod Biol. 2011. PMID: 21620558
-
[Tocolysis. Atosiban, an ocytcin-receptor antagonist].J Gynecol Obstet Biol Reprod (Paris). 2001 May;30(3):238-45. J Gynecol Obstet Biol Reprod (Paris). 2001. PMID: 11397999 Review. French.
Cited by
-
Atosiban Combined with Ritodrine for Late Threatened Abortion or Threatened Premature Labor Patients with No Response to Ritodrine: A Clinical Trial.Med Sci Monit. 2021 Mar 18;27:e929743. doi: 10.12659/MSM.929743. Med Sci Monit. 2021. PMID: 33731666 Free PMC article. Clinical Trial.
-
Nanotechnologies in Obstetrics and Cancer during Pregnancy: A Narrative Review.J Pers Med. 2022 Aug 17;12(8):1324. doi: 10.3390/jpm12081324. J Pers Med. 2022. PMID: 36013273 Free PMC article. Review.
-
Efficacy and side effect of ritodrine and magnesium sulfate in threatened preterm labor.Obstet Gynecol Sci. 2018 Jan;61(1):63-70. doi: 10.5468/ogs.2018.61.1.63. Epub 2017 Dec 27. Obstet Gynecol Sci. 2018. PMID: 29372151 Free PMC article.
-
Placental homing peptide guides HIF1α‑silenced exosomes conjugates for targeted enhancement of invasion of trophoblast cells.Mol Med Rep. 2023 Jul;28(1):135. doi: 10.3892/mmr.2023.13022. Epub 2023 May 26. Mol Med Rep. 2023. PMID: 37232338 Free PMC article.
-
Sulfation of ritodrine by the human cytosolic sulfotransferases (SULTs): Effects of SULT1A3 genetic polymorphism.Eur J Pharmacol. 2015 Aug 15;761:125-9. doi: 10.1016/j.ejphar.2015.04.039. Epub 2015 May 2. Eur J Pharmacol. 2015. PMID: 25941087 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources